Annu Int Conf IEEE Eng Med Biol Soc. 2021 Nov;2021:2197-2200. doi: 10.1109/EMBC46164.2021.9630187.
Currently, there is an increasing number and speed of SARS-CoV-2 mutation taking place around the world, posing a threat to promising public health and challenge to existing diagnostic tools. RT-PCR technology is recognized as the gold standard diagnosing methodology but has shown inaccuracy under some mutated SARS-CoV-2 circumstances. In this study, we developed a platform named SCOPE2 (Sars-COv-2 Primer covErage Evaluation) based on our previous publication. Testing by commonly-used SARS-COV-2 PCR primers, SCOPE2 is proved to effectively and efficiently assess the quality in terms of detection coverage, which may provide a practical tool for primer selection acceleration and primer design improvement.Clinical Relevance-This assists in single SARS-COV-2 Primer selection and suggestion of different SARS-COV-2 Primer combinations.
目前，全球范围内 SARS-CoV-2 突变的数量和速度不断增加，这对公共卫生构成了威胁，也对现有诊断工具提出了挑战。实时聚合酶链反应（RT-PCR）技术被认为是诊断的金标准方法，但在某些突变的 SARS-CoV-2 情况下显示出了不准确性。在本研究中，我们基于之前的出版物开发了一个名为 SCOPE2（Sars-CoV-2 Primer covErage Evaluation）的平台。通过对常用的 SARS-CoV-2 PCR 引物进行测试，SCOPE2 被证明能够有效地评估检测覆盖范围的质量，这可能为引物选择加速和引物设计改进提供一种实用工具。临床相关性——这有助于选择单个 SARS-CoV-2 引物，并建议使用不同的 SARS-CoV-2 引物组合。
